The FDA approval of Jewel Patch-WCD affirms its clinical safety and effectiveness and solidifies Element Science's leadership in wearable life-saving cardiovascular technology.


About the Jewel® Patch Wearable Cardioverter Defibrillator (Patch-WCD)

The Jewel® Patch-WCD is a novel, water resistant wearable cardioverter defibrillator designed to detect and treat life-threatening arrhythmias in patients with a temporary elevated risk for SCA. The device continuously monitors a patient’s heart and treats specific life-threatening rhythms. It is designed for continued protection during normal daily activities, including showering, sleeping, and moderate exercise. The Jewel Mobile App enables timely patient care by transmitting therapy information to the patient’s medical team in near real-time.


About Element Science, Inc.
Element Science, Inc. is a medical device and digital health company focused on developing solutions at the intersection of clinical-grade wearables, machine learning algorithms, and lifesaving therapies that address leading causes of death and hospitalization in patients with heart disease, primarily as they transition from the hospital-to-home. By putting the needs of patients and physicians first, our personalized digital devices, which are designed for function, comfort, and ease-of-use, aim to redefine the paradigm of care for these patients. Our first product, the Jewel® Patch Wearable Cardioverter Defibrillator, is initially targeted at treating more than 500,000 patients in the U.S. and Europe with an elevated temporary risk of potentially experiencing a lethal heart rhythm. Based in San Francisco, our founders include Third Rock Ventures, Google Ventures, Deerfield Management, Qiming Venture Partners USA, Cormorant Asset Management, and Invus Opportunities.

Back to HCB News

Products and Clearances Homepage